JP5060312B2 - 鉄(iii)錯化合物の用途 - Google Patents
鉄(iii)錯化合物の用途 Download PDFInfo
- Publication number
- JP5060312B2 JP5060312B2 JP2007554530A JP2007554530A JP5060312B2 JP 5060312 B2 JP5060312 B2 JP 5060312B2 JP 2007554530 A JP2007554530 A JP 2007554530A JP 2007554530 A JP2007554530 A JP 2007554530A JP 5060312 B2 JP5060312 B2 JP 5060312B2
- Authority
- JP
- Japan
- Prior art keywords
- iron
- iii
- use according
- complex compound
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/295—Iron group metal compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
parameter.html)に挙げられている。
血液学的評価
静脈血を、120人の被験者全員から、真空試験管を使用して取り、血液パラメータの全てをシスマックス血液検査で分析した。血清を血液サンプルから分離し、−20℃で保存した。血清サンプルを、標準的な方法(NIN−マニュアル1983)によって、SFe測定およびTIBC測定を行った。TSをSFeおよびTIBCから計算し、パーセントで表した。血清フェリチン分析を、「酵素結合免疫測定法」(ELISA)を使用して行った。
好中球およびリンパ球を、一段式倍密度勾配法により新鮮な血液サンプルから分離し、以下の免疫測定を、120人の被験者全員に対して行った。
−MTT法を使用するフィトヘマグルチニン(PHA)へのリンパ球反応;
−好中球を使用するニトロブルーテトラゾリウム試験(MBT);
−比濁法によって測定する好中球(BCA)の殺菌能
−麻疹、インフルエンザウィルスおよび破傷風に対する抗体応答;
−半定量的方法を使用するC−反応性タンパク質
120人の被験者の認識機能および情動行動を、最も頻繁に使用される試験に従って、および確立した方法に従って測定した。
1.短期記憶テスト(STM)
2.長期記憶テスト(LTM)
3.ラーベン漸進性マトリシーズ(RPM)
4.ウェクスラー成人知能検査(WAIS)
5.情動係数(バロンEQ−i;YVテスト;若年型)
120人の被験者の学校における成績を、学校の学力試験によって個々に確認した。
継続する時間でのパラメータの平均値の比較によって、治療の効果の実態がわかる。評価の特性は、反復測定を必要とすることを意味した。各パラメータに関し、3組の観察を行い、これらは全て相関性が見られた。したがって反復測定試験は適切な方法で、統計的分析を、SPSSソフトウェアを使用して行った。方法は、グループ間の継続期間(時点)のパラメータ値の有意性および、もし存在する場合は、継続期間とグループとの間の相互作用を試験する。異なるグループの間で複数の比較を、LSD(最小有意識別試験)を補助として、反復測定試験により自動的に行った。
有利な効果が、行った全ての試験、すなわち、血液学的状態、免疫状態、認識機能および情動行動に関して見出された。
Claims (8)
- 鉄欠乏症貧血または鉄欠乏症のない患者の免疫防御および/または脳特性を改善する医薬の製造における、炭水化物またはその誘導体との鉄(III)錯化合物の使用であって、該鉄(III)錯化合物が、鉄(III)−ポリマルトース錯化合物または1以上のマルトデキストリンの酸化生成物との鉄(III)錯化合物である使用。
- 鉄(III)−ポリマルトース錯化合物の分子量が、20,000〜500,000ダルトンの範囲である請求項1記載の使用。
- 鉄(III)−ポリマルトース錯化合物が、水酸化鉄(III)−ポリマルトース錯化合物である請求項1または2記載の使用。
- 1以上のマルトデキストリンの酸化生成物との鉄(III)錯化合物が、鉄(III)塩水溶液と、1以上のマルトデキストリンの次亜塩素酸水溶液とのアルカリ範囲内のpH値での酸化による生成物の水溶液とから得られる水溶性鉄−炭水化物錯化合物であり、デキストロース当量が5〜37のマルトデキストリンを使用し、かつ複数のマルトデキストリンの混合物を使用する場合、該混合物のデキストロース当量は5〜37であり、前記混合物に含まれる個々のマルトデキストリンのデキストロース当量は2〜40である請求項1記載の使用。
- 経口または非経口投与用の前記の鉄欠乏症貧血または鉄欠乏症のない患者の免疫防御および/または脳特性を改善する医薬の製造における請求項1〜4のいずれか一項に記載の使用。
- 小児、青少年または成人を治療するための前記の鉄欠乏症貧血または鉄欠乏症のない患者の免疫防御および/または脳特性を改善する医薬の製造における請求項1〜5のいずれか一項に記載の使用。
- 医薬が、錠剤、水溶液あるいは乳濁液の形態、顆粒剤、カプセルあるいはゲルの形態、または分包剤の形態で存在する請求項1〜6のいずれか一項に記載の使用。
- フィトヘマグルチニンに対するリンパ球反応により測定される、好中球レベル、抗体レベルおよび/またはリンパ球機能を改善するための、前記の鉄欠乏症貧血または鉄欠乏症のない患者の免疫防御および/または脳特性を改善する医薬の製造における請求項1〜7のいずれか一項に記載の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05100907.4 | 2005-02-09 | ||
EP05100907 | 2005-02-09 | ||
PCT/EP2006/050276 WO2006084782A1 (de) | 2005-02-09 | 2006-01-18 | Verwendung von eisen(iii)-komplexverbindungen |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008530049A JP2008530049A (ja) | 2008-08-07 |
JP5060312B2 true JP5060312B2 (ja) | 2012-10-31 |
Family
ID=34938674
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007554530A Expired - Fee Related JP5060312B2 (ja) | 2005-02-09 | 2006-01-18 | 鉄(iii)錯化合物の用途 |
Country Status (26)
Country | Link |
---|---|
US (2) | US8722101B2 (ja) |
EP (1) | EP1848446B1 (ja) |
JP (1) | JP5060312B2 (ja) |
KR (1) | KR20070107106A (ja) |
CN (1) | CN101155593A (ja) |
AT (1) | ATE445406T1 (ja) |
AU (1) | AU2006212322B2 (ja) |
BR (1) | BRPI0606974A2 (ja) |
CA (1) | CA2597154C (ja) |
CR (1) | CR9300A (ja) |
CY (1) | CY1109685T1 (ja) |
DE (1) | DE502006005100D1 (ja) |
DK (1) | DK1848446T3 (ja) |
ES (1) | ES2333814T3 (ja) |
HR (1) | HRP20100027T1 (ja) |
IL (1) | IL185020A (ja) |
MX (1) | MX2007009588A (ja) |
NO (1) | NO20074536L (ja) |
PL (1) | PL1848446T3 (ja) |
PT (1) | PT1848446E (ja) |
RU (1) | RU2359680C2 (ja) |
SI (1) | SI1848446T1 (ja) |
TN (1) | TNSN07307A1 (ja) |
UA (1) | UA88347C2 (ja) |
WO (1) | WO2006084782A1 (ja) |
ZA (1) | ZA200707716B (ja) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10249552A1 (de) * | 2002-10-23 | 2004-05-13 | Vifor (International) Ag | Wasserlösliche Eisen-Kohlenhydrat-Komplexe, deren Herstellung und diese enthaltende Arzneimittel |
CA2635894C (en) | 2006-01-06 | 2017-09-12 | Luitpold Pharmaceuticals, Inc. | Methods and compositions for administration of iron |
EP2165713B1 (en) * | 2008-09-19 | 2012-11-14 | Nestec S.A. | Whey and thymus function |
CA2756580A1 (en) * | 2009-03-25 | 2010-09-30 | Hans Andreasen | A stable iron oligosaccharide compound |
WO2012104204A1 (en) | 2011-01-31 | 2012-08-09 | Vifor (International) Ag | Iron-carbohydrate complex compounds for the intravenous therapy of malaria |
US11395502B2 (en) * | 2012-10-18 | 2022-07-26 | Patrick Monsivais | Formulation for iron supplements |
RU2015146368A (ru) * | 2013-03-28 | 2017-05-04 | Вифор (Интернациональ) Аг | КОМПЛЕКСНЫЕ СОЕДИНЕНИЯ Fe(III) ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ СИМПТОМОВ ЖЕЛЕЗОДЕФИЦИТНОЙ АНЕМИИ И СИДЕРОПЕНИЧЕСКОЙ АНЕМИИ |
KR20150078375A (ko) * | 2013-12-30 | 2015-07-08 | 한화케미칼 주식회사 | 철산화물 나노입자를 포함하는 철결핍증의 예방 또는 치료용 약학 조성물 |
FR3075001B1 (fr) * | 2017-12-14 | 2021-09-10 | Tereos Starch & Sweeteners Belgium | Utilisation des maltodextrines pour ameliorer la cognition et/ou stimuler le developpement du cerveau |
CN114288320A (zh) * | 2021-12-29 | 2022-04-08 | 珠海天翼医药技术开发有限公司 | 一种猪用口服补铁剂及其制备方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3076798A (en) * | 1961-02-23 | 1963-02-05 | Hausmann Lab Ltd | Process for preparing a ferric hydroxide polymaltose complex |
US3766165A (en) * | 1966-08-17 | 1973-10-16 | Pfizer | Polysaccharides and their preparation |
DE4421159C1 (de) | 1994-06-20 | 1995-08-24 | Thomas Bruns | Verwendung von Eisen(III)-oxid (Fe¶2¶O¶3¶) bei Immunschwäche |
DE19734293A1 (de) * | 1997-08-08 | 1999-02-11 | Boehringer Mannheim Gmbh | Verwendung von pharmazeutischen Kombinationspräparaten enthaltend Erythropoietin und Eisenpräparate zur Behandlung von rheumatischen Erkrankungen |
RU2003121403A (ru) | 2000-12-07 | 2004-12-27 | АД "ЗДРАВЛЬЕ" Фармасеутско-кемийска индустри , Сентар за истразиванье и развой (YU) | Полиядерный комплекс fe(iii) с олигомерами пуллулана, способ его получения и фармацевтические препараты на его основе |
EP1377594A4 (en) * | 2001-04-10 | 2004-06-30 | Danisco Usa Inc | POLYMERIZATION OF MONO AND DISACCHARIDES WITH MONOCARBOXYLIC ACIDS AND LACTONS |
NZ535761A (en) | 2002-04-09 | 2007-09-28 | Pharmacosmos Holding As | Iron dextrin compounds for the treatment of iron deficiency anaemia |
DE10249552A1 (de) | 2002-10-23 | 2004-05-13 | Vifor (International) Ag | Wasserlösliche Eisen-Kohlenhydrat-Komplexe, deren Herstellung und diese enthaltende Arzneimittel |
-
2006
- 2006-01-18 US US11/815,568 patent/US8722101B2/en not_active Expired - Fee Related
- 2006-01-18 RU RU2007133509/15A patent/RU2359680C2/ru not_active IP Right Cessation
- 2006-01-18 SI SI200630432T patent/SI1848446T1/sl unknown
- 2006-01-18 AU AU2006212322A patent/AU2006212322B2/en not_active Ceased
- 2006-01-18 EP EP06707742A patent/EP1848446B1/de active Active
- 2006-01-18 ES ES06707742T patent/ES2333814T3/es active Active
- 2006-01-18 PL PL06707742T patent/PL1848446T3/pl unknown
- 2006-01-18 KR KR1020077020249A patent/KR20070107106A/ko not_active Application Discontinuation
- 2006-01-18 UA UAA200708978A patent/UA88347C2/ru unknown
- 2006-01-18 JP JP2007554530A patent/JP5060312B2/ja not_active Expired - Fee Related
- 2006-01-18 PT PT06707742T patent/PT1848446E/pt unknown
- 2006-01-18 BR BRPI0606974-6A patent/BRPI0606974A2/pt not_active IP Right Cessation
- 2006-01-18 CA CA2597154A patent/CA2597154C/en not_active Expired - Fee Related
- 2006-01-18 AT AT06707742T patent/ATE445406T1/de active
- 2006-01-18 WO PCT/EP2006/050276 patent/WO2006084782A1/de active Application Filing
- 2006-01-18 MX MX2007009588A patent/MX2007009588A/es active IP Right Grant
- 2006-01-18 CN CNA2006800115263A patent/CN101155593A/zh active Pending
- 2006-01-18 DK DK06707742.0T patent/DK1848446T3/da active
- 2006-01-18 DE DE502006005100T patent/DE502006005100D1/de active Active
-
2007
- 2007-08-02 IL IL185020A patent/IL185020A/en not_active IP Right Cessation
- 2007-08-08 TN TNP2007000307A patent/TNSN07307A1/en unknown
- 2007-08-09 CR CR9300A patent/CR9300A/es unknown
- 2007-09-07 NO NO20074536A patent/NO20074536L/no not_active Application Discontinuation
- 2007-09-07 ZA ZA200707716A patent/ZA200707716B/xx unknown
-
2009
- 2009-12-14 CY CY20091101333T patent/CY1109685T1/el unknown
-
2010
- 2010-01-14 HR HR20100027T patent/HRP20100027T1/hr unknown
-
2014
- 2014-03-10 US US14/202,056 patent/US20140187514A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
SI1848446T1 (sl) | 2010-01-29 |
AU2006212322A1 (en) | 2006-08-17 |
AU2006212322B2 (en) | 2012-01-19 |
ATE445406T1 (de) | 2009-10-15 |
CN101155593A (zh) | 2008-04-02 |
MX2007009588A (es) | 2007-09-12 |
RU2007133509A (ru) | 2009-03-20 |
BRPI0606974A2 (pt) | 2009-07-28 |
RU2359680C2 (ru) | 2009-06-27 |
PT1848446E (pt) | 2009-12-21 |
ZA200707716B (en) | 2008-06-25 |
EP1848446B1 (de) | 2009-10-14 |
ES2333814T3 (es) | 2010-03-01 |
WO2006084782A1 (de) | 2006-08-17 |
US20140187514A1 (en) | 2014-07-03 |
IL185020A (en) | 2013-10-31 |
NO20074536L (no) | 2007-11-05 |
DK1848446T3 (da) | 2010-02-15 |
TNSN07307A1 (en) | 2008-12-31 |
CA2597154C (en) | 2011-03-15 |
UA88347C2 (ru) | 2009-10-12 |
IL185020A0 (en) | 2007-12-03 |
CY1109685T1 (el) | 2014-08-13 |
US8722101B2 (en) | 2014-05-13 |
CR9300A (es) | 2007-12-07 |
DE502006005100D1 (de) | 2009-11-26 |
KR20070107106A (ko) | 2007-11-06 |
CA2597154A1 (en) | 2006-08-17 |
PL1848446T3 (pl) | 2010-03-31 |
HRP20100027T1 (hr) | 2010-02-28 |
US20080214496A1 (en) | 2008-09-04 |
JP2008530049A (ja) | 2008-08-07 |
EP1848446A1 (de) | 2007-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5060312B2 (ja) | 鉄(iii)錯化合物の用途 | |
US4514421A (en) | Dietary and pharmaceutical uses of methylsulfonylmethane and compositions comprising it | |
JP4997241B2 (ja) | 慢性炎症性腸疾患の患者における鉄欠乏状態の経口処置用の薬剤を調製するための鉄(iii)複合化合物 | |
ES2732290T5 (es) | Compuestos de complejo de hierro-hidrato de carbono | |
Emmerich et al. | Local immunity in patients with chronic bronchitis and the effects of a bacterial extract, Broncho-Vaxom®, on T lymphocytes, macrophages, gamma-interferon and secretory immunoglobulin A in bronchoalveolar lavage fluid and other variables | |
JP2009517359A (ja) | 三価鉄錯体およびレドックス活性物質を含有する薬剤 | |
Makonnen et al. | A randomized controlled study of the impact of dietary zinc supplementation in the management of children with protein–energy malnutrition in Lesotho. I: Mortality and morbidity | |
EP2338495A1 (en) | Iron bis-glycinate chelate for use in the oral treatment of anemia in patients with celiac disease | |
HARDWICK et al. | Near fatal fire ant envenomation of a newborn | |
Schindel | Unexpected Reactions to Modern Therapeutics: Antibiotics | |
RU2406506C1 (ru) | Фармацевтическая композиция холин альфосцерата в форме раствора для инъекций (холитилин®), обладающая ноотропной активностью и холиномиметическим действием, способ лечения/профилактики заболеваний цнс и последствий черепно-мозговых травм | |
US20180133292A1 (en) | Enzyme-treated milk product, preparation method thereof, composition, and products | |
JP6811983B2 (ja) | 網膜神経節細胞死抑制活性を有する経口用組成物 | |
EP2606885B1 (en) | Medicinal preparation "renessans" having an antibacterial, anti-ulcerous and immuno-modulating action | |
Lolekha et al. | Immunogenicity and safety of two doses of a paediatric hepatitis A vaccine in Thai children: comparison of three vaccination schedules | |
JP7291380B2 (ja) | 鼻水又は鼻づまりの口腔粘膜投与用即効性改善剤 | |
EP3777887A1 (en) | Allergenic action enhancer comprising hyaluronic acid as active ingredient | |
JPWO2006085523A1 (ja) | 血糖値上昇抑制用組成物 | |
OA21266A (en) | Dicarboxylic acid esters for inducing an analgesic effect. | |
Nuncã et al. | THE ROLE OF GENERAL FACTORS IN THE PATHOGENESIS OF ORAL CANDIDIASIS | |
JPS584724A (ja) | 免疫賦活剤 | |
CA3202461A1 (en) | Dicarboxylic acid esters for inducing an analgesic effect | |
RU2466722C2 (ru) | Противотуберкулезное средство | |
JP2019214546A (ja) | 終末糖化産物生成抑制剤及び医薬組成物 | |
Island | DEXA MEDICA, KPI WINNER2005 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110524 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110819 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110826 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110922 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110930 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111024 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111031 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111121 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20111213 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120413 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20120501 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20120606 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20120703 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120724 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120803 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150810 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |